U.K. cost watchdog rejects Roche, GSK cancer meds

The U.K. hasn't been kind to high-tech cancer drugs this week: The cost-effectiveness watchdog NICE rejected Roche's Herceptin and GlaxoSmithKline's Tykerb for use in breast cancer patients in combination with hormone-blocking drugs; and Roche's Avastin got stiff-armed as a treatment for colorectal cancer that has spread. Article | Report